Gene Panel Market

Market CAGR for gene panels is being driven by the rising cases of chronic diseases. The growing burden of chronic diseases that are associated with genes like heart attack, stroke, cancer, arthritis, and others is anticipated to boost the market growth. Further, the increasing number of product approval and launches is foreseen to boost the  gene panel market throughout the forecast period. The rising variety in the cases of cancers in females and males both and the benefits offered by the gene panel market.

A gene panel is a test that helps to analyze multiple genes at the same time for cancer-associated mutations. This test has the ability to examine a various genes that helps in providing information related to cancer and also offers a secure diagnostic that assists in preventing cancer from spreading. The growing number of cancer cases of different types, including breast cancer, cancer of the ovaries, fallopian tubes, and prostate cancer in men, and rising frequencies of chronic diseases throughout the world are the main factor boosting the gene panel market.

Further, a growing number of initiatives taken by different companies worldwide and other benefits of gene panels are the prime reasons favoring the growth of the gene panel market. As per the Genetic and Rare Disease Information Center, there are around 7,000 diagnosed genetic conditions, and the list is continuously increasing. Several gene panels are fabricated to detect genetic disorders at birth so that effective therapeutic steps and prognoses can be taken as early as possible.

The Global Gene Panel Market Industry is poised for substantial growth, with projections indicating a market value of 1.42 USD Billion in 2024 and an anticipated increase to 5.85 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 13.73% from 2025 to 2035. Such figures highlight the increasing reliance on genetic testing in clinical settings and the expanding applications of gene panels across various medical fields. The upward trend in market value suggests a robust demand for innovative genetic solutions that address the complexities of human health.

Regulatory bodies are increasingly supporting the use of genetic testing, which positively impacts the Global Gene Panel Market Industry. Policies that promote the integration of genetic testing into standard healthcare practices enhance accessibility and adoption. For instance, the U.S. Food and Drug Administration has streamlined the approval process for genetic tests, encouraging innovation and market entry. This regulatory environment fosters confidence among healthcare providers and patients alike, leading to a projected market growth from 1.42 USD Billion in 2024 to 5.85 USD Billion by 2035, as gene panels become integral to routine clinical practice.

The increasing incidence of genetic disorders globally drives the Global Gene Panel Market Industry. As healthcare systems become more adept at diagnosing these conditions, the demand for gene panels rises. For instance, the World Health Organization reports that genetic disorders affect approximately 1 in 1,600 births. This growing awareness and diagnosis lead to a projected market value of 1.42 USD Billion in 2024, with expectations to reach 5.85 USD Billion by 2035. The compound annual growth rate of 13.73% from 2025 to 2035 indicates a robust expansion in this sector, reflecting the urgent need for advanced genetic testing solutions.

The shift towards personalized medicine is a pivotal driver of the Global Gene Panel Market Industry. Patients and healthcare providers increasingly seek tailored treatment options based on genetic profiles. Gene panels play a critical role in identifying specific mutations that inform treatment decisions. This trend is evident in oncology, where targeted therapies are developed based on genetic testing results. The market's growth, projected at a CAGR of 13.73% from 2025 to 2035, underscores the importance of gene panels in delivering personalized healthcare solutions that improve patient outcomes and optimize therapeutic strategies.

The Global Gene Panel Market Industry benefits from heightened investment in genomic research. Governments and private entities are allocating substantial resources to explore genetic factors influencing health. For example, the National Institutes of Health in the United States has significantly increased funding for genomic studies. This influx of capital fosters innovation in gene panel development, enhancing their capabilities and applications. The market is projected to grow from 1.42 USD Billion in 2024 to 5.85 USD Billion by 2035, driven by the need for advanced research tools that can facilitate breakthroughs in understanding genetic diseases.

Technological innovations in genomic testing significantly bolster the Global Gene Panel Market Industry. Advances in next-generation sequencing and bioinformatics enhance the accuracy and efficiency of gene panels. These developments allow for comprehensive genetic analysis, which is crucial for personalized medicine. As a result, healthcare providers increasingly adopt these technologies, leading to a surge in market demand. The anticipated growth trajectory, with a market value of 1.42 USD Billion in 2024, suggests that the industry is on the cusp of a technological revolution that could redefine genetic testing practices and patient outcomes.

By region, the study gives market insights into the North America, Europe, Asia-Pacific, and the Rest of the World. The North American Gene Panel market area dominates the market due to the extensive research that are carried out in different research institutes collaboratively sponsored by academic research institutes, National Cancer Institutes, and pharmaceutical giants throughout the region. The US is the largest contributor to the growth of the gene panel market in the North American region.

Further, the prime countries studied in the market report are the US, Canada, France, German, the UK, Italy, Spain, Japan, India, China, Australia, South Korea, and Brazil.

Figure 2 GENE PANEL MARKET SHARE BY REGION 2022 (USD Billion)

Source The Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe Gene Panel market accounts for the second-largest market revenue due to the rise in the number of cases of cancer and increasing investment in research and development made by various organizations. Further, the German Gene Panel market held the largest market share, and the UK Gene Panel market was the rapid-growing market in European region.

The Asia-Pacific Gene Panel Market is expected to grow at the rapid CAGR from 2023 to 2032. This is due to the rising expenditure on healthcare facilities by the government and the presence of highly populous countries in this region. Moreover, China’s Gene Panel market held the largest market share, and the Indian Gene Panel market was the rapid-growing market in Asia-Pacific region.

Leading market players are investing hugely in research and development in order to expand their product lines, which will help the Gene Panel market grow even more. Market players are also undertaking a variety of strategic activities to spread their footprint, with important market developments including new product launches, higher investments, contractual agreements, mergers and acquisitions, and collaboration with other organizations. To spread and survive in a more competitive and rising market climate, the Gene Panel industry must offer cost-effective items.

Manufacturing locally to minimize the operational costs is one of the key business tactics used by the manufacturers in the Gene Panel industry to benefit clients and  the market sector. In recent years, the Gene Panel industry has offered some of the most significant advantages to the biotechnology industry. Major players in the Gene Panel market, including Eurofins Genomics, Illumina Inc, Gencove, Centogene NV, Myriad Genetic Laboratories Inc., Agilent Technologies, Thermo Fisher Scientific, Foundation Medicine Inc., Bio-Rad Laboratories Inc., Guardant Health Inc., others, are attempting to increase market demand by investing in research and development operations.

Gencove, a US-based biotechnology company founded in the year 2015, is the provider of information proposed to make genome sequencing technologies more accessible and analyzed. The company makes molecular and computational tools for enabling high-throughput and low-cost genome sequencing technologies for industries like agriculture and pharma, allowing the researchers to have access to genomic data.

In January 2021, the company and BGI Americas Corporation, which is a subsidiary of BGI Genomics in the US, announced the extension of collaboration which was intended to combine sequencing assistance BGI using proprietary DNBSEQ sequencing technologies with the evaluation interface of Gencove in order to use high-capacity, cost-effective whole genome data for actionable tasks.

Illumina Inc is an American biotechnology company founded in the year 1998, headquartered in San Diego, California, serving more than 140 countries. The company develops, produces, and sells integrated systems for the interpretation of genetic variation and biological function, providing a line of services and products that serves the genotyping, sequencing, gene expression, and proteomics markets. The company sells a variety of high-throughput DNA sequencing systems, depending on technology developed by Solexa.

In March 2022, the company launched the TruSight Oncology Comprehensive test in the European region, which can capably evaluate a total of 517 tumor genes throughout 30 types of cancer and biomarkers to be able to gain specific individual molecular profiles. The test evaluates peculiar genomic signatures like tumor mutational burden and microsatellite instability.